



Press release

Cantargia AB
556791-6019
15 May 2019

Cantargia: abstract published for the oral presentation of antibody CAN04 phase I data at ASCO

Cantargia AB today announces that the abstract of the upcoming oral presentation of CAN04 phase I clinical data at the 2019 ASCO Annual Meeting is published on the conference website. The abstract reports available data on the 22 patients in the phase I trial based on the interim analysis performed in February 2019. These data show that the safety profile of CAN04 was good and that CAN04 treatment led to a decrease of the biomarkers IL-6 and CRP already after two weeks of therapy. Nine patients had stable disease as determined by irRC after eight weeks follow up. One patient with pancreatic cancer had stable disease at the four months evaluation and one with non-small cell lung cancer (NSCLC) had stable disease at six months. Updated data will be given at the presentation June 2, 2019.

Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through ADCC and blockade of interleukin 1 signaling. CAN04 is investigated in a phase I/IIa clinical trial examining monotherapy as well as combination with two different chemotherapy regimes in patients with NSCLC or pancreatic cancer (www.clinicaltrials.gov). The phase I monotherapy part also included patients with colorectal cancer.

As previously announced, the phase I monotherapy data on CAN04 has been selected for oral presentation at the annual ASCO conference in Chicago, May 31-June 4, 2019. The results will be presented by the coordinating investigator, Professor Ahmad Awada from Inst. Jules Bordet in Brussels. The presentation is titled: Results from a First-in-man, Open label, Safety and tolerability Trial of CAN04 (Nidanilimab), a Fully Humanized Monoclonal Antibody against the Novel Antitumor Target, IL1RAP, in Patients with Solid Tumor Malignancies. The abstract can now be accessed through the conference web site www.asco.org and is based on the results that were available at the time of submission in February 2019.

In summary, 22 patients were treated. The safety profile was good. Adverse events occurred mainly following the first dose and the most common AEs were: infusion related reaction (IRR) (41%), pyrexia (27%), fatigue (23%), chills (23%) and nausea (23%). Grade 3 adverse events were one IRR, one neutropenia/leukopenia and one hypokalemia, and no grade 4 events were noted. Serum levels of the biomarkers CRP and IL-6 were reduced after two weeks of treatment. Nine patients had stable disease by irRC at eight weeks follow up. Two patients, one with NSCLC and one with pancreatic cancer, had stable disease at six and four months.

"The ASCO Annual Meeting is the major conference for clinical cancer research and it is very exciting that the CAN04 results were selected for oral presentation. We are encouraged by the results obtained so far and look forward to present complete results at ASCO", Göran Forsberg, Cantargia's CEO says.

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 23.30 CET on 15 May 2019.

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is conducting both monotherapy and combination therapy. Cantargia's other project, CANxx, is in the research phase and is aiming to develop a IL1RAP binding antibody optimised for the treatment of autoimmune and inflammatory diseases.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at <http://www.cantargia.com>.